itor sorafenib (Nexavar; co-developed and co-marketed by Bayer and Onyx Pharmaceuticals), 14 which in addition to FLT3 also has VEGFR-1-3, PDGFR-β, RET and c-KIT as targets. Second-generation FLT3 inhibitors include quizartinib (AC220; Daiichi Sankyo), 15, 16 a highly selective inhibitor of FLT3-ITD that does not inhibit FLT3-TKD (D835 or F691) in patients, 17 crenolanib besylate (CP-868596; AROG Pharmaceuticals, LLC), 18 which has FLT3-ITD and FLT3-TKD and PDGFR as targets, and the FLT3 and AXL inhibitor, gilteritinib (ASP2215, XOSPATA; Astellas Pharma US, Inc), 19, 20 which was FDA-approved for patients with relapsed or refractory AML with an identified FLT3 mutation, based on results of the ADMIRAL trial (NCT02421939).
As midostaurin has not been investigated largely in wt FLT3expressing AML pre-clinically, we sought to explore its activity in this context, alone and in combination, to better understand the observed clinical efficacy and inform best combinations for future clinical investigation. It has been shown that for AML patients to achieve maximum clinical benefit, it is imperative that midostaurin be administered in combination with other anticancer agents. 6, 8 Here, we investigate the effects of midostaurin alone against AML characterized as expressing either wt or mutant FLT3, as well as in combination with standard chemotherapy and targeted inhibitors.
Our results suggest that midostaurin, with its unique kinase profile and broad-spectrum activity, could potentially be used clinically as a chemosensitizing agent for AML patients expressing either mutated or non-mutated FLT3.
| MATERIAL S AND ME THODS

| Cell lines
Ba/F3 (interleukin [IL]-3-dependent murine pro-B) cells engineered to express SYK-TEL, TEL-SYK or FLT3-ITD, provided by Dr Kimberly Stegmaier (Dana-Farber Cancer Institute, MA), have been previously described. 21, 22 The human AML-derived, FLT3-ITD-expressing line, MOLM14, 23 More details are provided in Appendix S1.
| Chemical compounds and biologic reagents
Details are provided in the Appendix S1.
| Cell proliferation studies and apoptosis studies
| Immunoblotting
Protein lysate preparation and immunoblotting were carried out as previously described. 5 
| Antibodies
Antibodies purchased from Cell Signaling Technology were used at a dilution of 1:1000 and include phospho-S6 ribosomal protein (S235/236) (D57.2.2E) XP (R) (rabbit monoclonal, #4858), phospho-AKT (Ser 473) (D9E) XP(R) (rabbit mAb, #4060), phospho-p44/42 MAPK (T202/Y204) (rabbit, #9101), total AKT (rabbit, #9272), total MAPK (mouse, #9107), total S6 (rabbit, #2217), Mcl-1 (rabbit, #5453), Bcl-xL (rabbit, #2764), Bcl-2 (human specific, #2872) and beta-tubulin (rabbit polyclonal, #2146). Anti-GAPDH (14C10) (rabbit mAb, #2118) (Cell Signaling Technology) was used at a dilution of 1:3000.
| AML patient cells
Methodology is described in detail in Appendix S1.
| Drug combination studies
Methodology for drug combination studies 24 is described in detail in Appendix S1.
| Non-invasive in vivo bioluminescence studies
All animal studies were performed according to protocols approved by the Dana-Farber Cancer Institute's Institutional Animal Care and Use Committee.
Bioluminescence imaging was carried out as previously described. 25 Briefly, for administration to female NSG mice (6-8 weeks of age; The Jackson Laboratory, Bar Harbor, ME), virus-and Mycoplasmafree SKNO-1-luc+ cells or OCI-AML3-luc+ cells were washed and resuspended in 1X PBS and administered via IV tail vein injection (2 × 10 6 cells/250 µL PBS). A sample size of at least 8 mice per treatment group was chosen to ensure statistical significance. Anaesthetized mice were imaged 3 days after IV injection of cells to generate a baseline used to establish treatment cohorts and matched leukaemia burden (mice were randomized). Drug treatments were also started 3 days after inoculation. Total body luminescence was measured as previously described. 26 Mice were treated with vehicle (n = 10) or midostaurin (100 mg/kg) (n = 10) for 28 days by oral gavage qD. 80 mg/kg was the tolerated dose for midostaurin purchased from MedChemExpress, LC Labs and BOC Sciences, whereas 100 mg/kg was the tolerated dose for midostaurin received from Novartis Pharma AG. For the SKNO-1-luc+ xenograft study, midostaurin stocks were obtained from Novartis Pharma AG, LC Labs, BOC Sciences and MedChemExpress. For the OCI-AML3-luc+ xenograft study, midostaurin stock was obtained from Novartis Pharma AG.
Midostaurin was formulated as a pre-concentrate/microemulsion with 5% drug powder, 34% Vit E TPGS, 42.5% PEG400, 8.5% corn oil and 10% ethanol. The pre-concentrate was then dissolved in purified water at a 24:76 ratio the day of treatment.
For all in vivo studies, P < .05 was considered to be statistically significant. The data had similar variance and met the assumptions of the tests carried out. For in vivo studies investigating the single-agent effects of midostaurin, the Mann-Whitney test (two-tailed) was carried out to assess differences in leukaemia burden between vehicle and drug-treated mice and the Gehan-Breslow-Wilcoxon test was carried out for survival curve comparisons.
| RE SULTS
| Comparison of anti-proliferative effects of midostaurin and FLT3 inhibitors against wt FLT3expressing AML cell lines
Clinical trial results demonstrate efficacy of midostaurin in wt FLT3-expressing AML. 6, 8 Significantly, midostaurin and its major metabolites have been reported to have a number of kinase targets implicated in transformation and chemoresistance. 12 Although considerable pre-clinical and clinical data have been generated showing efficacy of midostaurin against mutant FLT3-positive AML, comparatively little is known about the effectiveness of midostaurin against AML expressing wt FLT3 and other driver oncogenes. Midostaurin and other, more targeted FLT3 inhibitors were thus investigated to better understand important targets.
We measured the efficacy of midostaurin and several advanced stage FLT3 inhibitors as single agents against human AML cell lines expressing either oncogenic FLT3 or wt FLT3. Midostaurin and the other FLT3 inhibitors, as expected, most potently suppressed the growth of FLT3-ITD-positive MOLM14 cells; however, the inhibitors effectively killed wt FLT3-expressing AML lines at submicromolar concentrations ( Figure 1A -E). As predicted, cell lines expressing an Asn822Lys mutation of KIT (SKNO-1-luc+ and Kasumi-1-luc+) 27, 28 were particularly sensitive to FLT3 inhibitors that have been reported to display strong mutant KIT inhibitory activity, including sorafenib and quizartinib 29, 30 ( Figure 1C -E).
The targeted SYK inhibitor, PRT062607, was included as a negative control in that it displays no FLT3 inhibitory activity. 22 As expected, mutant FLT3-expressing MOLM14 cells were significantly growth-inhibited by the panel of FLT3 inhibitors; however, PRT062607 showed much less potency against these cells ( Figure 1F ).
To better understand the mechanism of midostaurin against AML cells expressing either mutated or wt FLT3, we next examined its effects on signalling molecules, including those implicated in inhibiting apoptosis as well as those contributing to cellular transformation. Consistent with the characterization of midostaurin as pro-apoptotic, 5 Midostaurin also inhibited S6 phosphorylation in OCI-AML2 cells in a concentration-dependent manner, with robust inhibition observed at 500 nmol/L, although there was no inhibitory effect observed on AKT or MAPK phosphorylation in this cell line ( Figure S1H ). The utility of pS6 as a biomarker for the efficacy of midostaurin against wt FLT3-expressing AML was investigated by comparing drug effects on pS6 in AML cell lines that were around 2-fold or more sensitive to midostaurin (Kasumi-1-luc+, K052, OCI-AML2) than other AML cell lines (HEL, OCI-AML3). A decrease in pS6 was observed in midostaurin-treated Kasumi-1-luc+, K052 and OCI-AML2 at concentrations 250-500 nmol/L ( Figure 2F ). In contrast, there was no decrease in pS6 in HEL or OCI-AML3 cells treated at the same concentrations ( Figure 2F ). These results suggest that pS6 is a good biomarker for midostaurin activity and reflect the inhibition of MAPK signalling by midostaurin as a key component of its mechanism. Indeed, we have recently shown that pS6 is an excellent biomarker for activity of a targeted small molecule inhibitor of ERK1/2. 31 In addition to human cell lines, midostaurin and the other FLT3 inhibitors were also tested for efficacy against primary AML cells.
The inhibitors were observed to kill primary human AML cells having a high (>90) per cent of blasts and expressing either wt FLT3 or oncogenic FLT3 in a concentration-dependent fashion and to a greater extent than PBMCs from a normal donor, and with higher potency than PRT062607, used as a negative control because of its lack of FLT3 inhibitory activity ( Figure 3A Having established in vitro the anti-proliferative activity of midostaurin and other FLT3 inhibitors, we next asked whether midostaurin could disrupt the proliferative activity in in vivo models of wt FLT3expressing AML ( Figure 4 ). We first tested engraftment of SKNO-1-luc+ and Kasumi-1-luc+ cells, both of which express the KIT-N822K mutation as well as the t(8;21)(q22;q22) translocation that generates the RUNX1-RUNX1T1 fusion gene. 27, 28 As engraftment of SKNO-1-luc+ cells in mice was strikingly more efficient than engraftment of Kasumi- 
| SYK is a target of midostaurin but not of other FLT3 inhibitors in clinical development
The multi-targeted nature and unique properties of midostaurin offer potential clinical benefits that other inhibitors may not, including suppression of kinases other than FLT3, such as mutant KIT, which play a role in aberrant signalling characteristic of the transformed phenotype or that are implicated in stromal cell-mediated chemoresistance. 12 A recent study reported that SYK, a protein implicated in AML transformation and drug resistance, was among a panel of signalling molecules, including VEGFR2, LYN, IGF1R, RET, PDPK1 and TRKA, which were potently suppressed not only by midostaurin but also by its metabolites. 12 Consistent with this, we have previously reported that SYK is a target of midostaurin. 22 Figure 5D ). When effects of the FLT3 inhibitors against FLT3-ITD-expressing cells were compared with effects against activated SYK-expressing cells, there was a considerably smaller difference in the potency of midostaurin against the two oncoproteins than for the other FLT3 inhibitors ( Figure S4E-I) . In contrast, anti-proliferative effects of PRT062607 were much stronger against activated SYKexpressing cells than FLT3-ITD-expressing cells ( Figure S4J ). Table S1 . For AML2, no FLT3-ITD mutation was detected. For AML3, a FLT3-ITD mutation was detected (insertion of 12 nt 3′ to nt 1826, followed by a duplication of nt 1788-1826 (total = 51 bp); the ITD is 7% of the total flt3 alleles in the specimen; this normally corresponds to 14% blasts. However, the specimen had 93% blasts on the day of this analysis. There is a minor clone with a 51bp ITD. For AML5, no FLT3-ITD mutation was detected. Figure S7 ). Taken together, these data support the notion of targeted SYK suppression by midostaurin but not by the other FLT3 inhibitors.
| Midostaurin potentiates effects of standard chemotherapy
Midostaurin has high synergizing potential and is able to positively combine with a number of agents, Bcl-2 inhibitor ABT-263 (navitoclax), and the Mcl-1 inhibitor S63845, against mutant FLT3-expressing MOLM14 cells (Table 1; Figure S8 ).
As such, we similarly investigated the effects of combining midostaurin with the same chemotherapy agents and proviability signal- (Table 1 ; Figures S10 and S11). Combinations of midostaurin and 5-azacytidine or decitabine showed the highest degree of synergy across a wide range of concentrations and a number of wt FLT3-expressing cell lines (Table 1 ; Figures S10 and S11 ).
Additive to synergistic effects was similarly observed for many of the combinations of midostaurin with inhibitors of proviability signalling molecules, with some exceptions showing antagonism, including the combination of midostaurin with venetoclax against OCI-AML3 and HEL cells, and the combination of midostaurin with venetoclax or navitoclax against NOMO-1 cells ( Table 1 ; Figures S10 and S11) . Taken together, our data suggest that midostaurin is able to potentiate the effects of numerous other agents against wt FLT3-expressing AML.
| D ISCUSS I ON
Midostaurin has a potentially useful combination of targets that are involved in multiple key signalling pathways, and this multi-targeted behaviour may account for some of the observed efficacy of the inhibitor against numerous AML genotypes. In addition, considering that overexpression of wt FLT3 is characteristic of the majority of AML cases, the importance of inhibiting wt FLT3 may have been previously unappreciated. Early investigations revealed the potential of AML patients without mutations in FLT3 to be clinically responsive to midostaurin and are consistent with the results presented herein using our cell line-based and murine models of wt FLT3 AML. 8, 9 Specifically, in a Phase IIb study, haematologic improvement was observed in 16/35 AML patients harbouring FLT3 mutations and 20/57 AML patients expressing wt FLT3, and more than half of patients exhibited peripheral blood or bone marrow blast reduction independent of FLT3 mutational status, although with a higher overall incidence observed for mutant FLT3-positive patients. 8 Similarly, in a Phase I study, 100 mg midostaurin treatment twice daily led to complete responses in 8/23 wt FLT3-expressing patients and 5/56 mutant FLT3expressing patients, with 9 wt FLT3 patients and 2 mutant FLT3 patients surviving over 4 years. 9 For patients treated with 50 mg TA B L E 1 Combination indices generated by Calcusyn software for midostaurin combined with indicated chemotherapy agents or inhibitors of proviability signalling molecules against FLT3-ITD-positive MOLM14 cells (panel 1, top); combination indices generated by Calcusyn software for midostaurin combined with indicated chemotherapy agents against wt FLT3 AML cell lines (panel 2, middle); combination indices generated by Calcusyn software for midostaurin combined with inhibitors of proviability signalling molecules against wt Clinical benefit was also observed in the large Phase III RATIFY trial in AML patients regardless of their FLT3 mutant: FLT3 wt ratio and the type of FLT3 mutation they harboured. 6 Based on this, a multinational, randomized Phase III clinical trial has commenced, investigating the efficacy of midostaurin in combination with chemotherapy and also as single-agent maintenance therapy in newly diagnosed AML patients harbouring wt FLT3. 34 Treatment of AML patients with a FLT3 inhibitor as a single agent is not likely to lead to a complete remission and therefore combination with other agents can potentially provide more clinical benefit, as has previously been observed. 6 A benefit of combined use of FLT3 inhibitors with other agents is overriding of some forms of drug resistance. For example, midostaurin, through inhibition of the drug transport function of the ATP-binding cassette (ABC) protein ABCB1, resensitizes multidrug-resistant cancer cells to standard chemotherapeutic agents. 35 Whereas overall response rates of first-generation FLT3 inhibitors such as midostaurin as single agents have ranged from 0% to 3%, 8 overall response rates have been 20%-40% when these inhibitors were combined with standard chemotherapy. 36, 37 This is compared to an overall response rate of second-generation FLT3 inhibitors as single agents of 40%-50%; however, duration of response is short and haematologic recovery is incomplete for these inhibitors. 38 Other limitations of second-generation FLT3 inhibitors include a short (6-8 hours) half-life for crenolanib, requiring thrice-daily dosing, and a lack of activity of quizartinib against FLT3-TKD mutants such as those occurring at the D835 or F691
residues. 17 We demonstrated the ability of midostaurin to behave as a relatively high resistance to venetoclax as a single agent as has been previously reported. 39 We generally observed some combinations between midostaurin and standard chemotherapeutic agents to show stronger synergy than others, with comparatively weaker combination effects observed for the simultaneous administration of midostaurin+ Ara-C against both mutant FLT3-and wt FLT3-expressing cells. Sequential versus simultaneous administration of midostaurin and Ara-C against Ba/F3-FLT3-ITD-luc+ cells led to additive to synergistic effects that were generally comparable ( Figure S12 ). Our findings are consistent with a report of variable results for Ara-C+ midostaurin-treated AML cell lines and patient samples, with antagonistic effects observed frequently in wt FLT3-expressing cells (90%) and less so in FLT3-ITD-positive cells (60%), with little effect of the timing or sequence of the drug administration. 40 We examined FLT3 levels in all of the human AML lines used for our study ( Figure S13 ), and we observed variable expression of FLT3, ranging from no detectable FLT3 protein expression in HL60 cells to high expression in cell lines such as SKNO-1-luc+ and OCI-AML2 (highest FLT3 expression was observed in FLT3-ITDpositive MOLM14 cells). FLT3-null cells, such as HL60, showed moderate, submicromolar, sensitivity to midostaurin (IC50 near 250 nmol/L; Figure 1A) , which was similar to the sensitivity of other cell lines with detectable FLT3, such as NOMO-1, OCI-AML3 and HEL. If FLT3 null patients, similar to the FLT3 null HL60 cell line model, respond to midostaurin, then this could be attributed to the broad-spectrum activity of midostaurin, independent of FLT3 as a target.
We also tested the responsiveness of the AML cell lines to midostaurin when cultured in the presence versus the absence of FLT3 ligand, to investigate whether cell line sensitivity to midostaurin correlated with the level of FLT3 expression in the different cell lines. As expected, the presence of FLT3 ligand did not appear to significantly affect cell proliferation for null FLT3-or wt FLT3-expressing AML lines treated with midostaurin, and the high or low expression of FLT3 in the different cell lines did not seem to affect their sensitivity to midostaurin in the presence of FLT3 ligand ( Figure S13 ).
Encouraging results were recently reported for midostaurin in a 'real-world' setting, namely higher remission rates in midostaurin-treated patients that translated into an increased rate of transplantation in first remission. 41 These promising clinical responses, coupled with pre-clinical and clinical studies suggesting efficacy of midostaurin in mutant FLT3 as well as non-mutated FLT3-expressing patients, strongly support the investigation of midostaurin as a therapeutic for a more general population of AML patients. 
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